Trial Profile
Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2021
Price :
$35
*
At a glance
- Drugs ACTR707 (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Cogent Biosciences
- 02 Mar 2020 Status changed from recruiting to discontinued, according to an Unum Therapeutics media release.
- 06 Nov 2019 Results (n=6) released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).
- 04 Nov 2019 According to an Unum Therapeutics media release, the company plans to enroll two additional cohorts (three to four patients per cohort) in the trial, escalating the maximum dose up to 180M ACTR707+ T cells. Patient screening and dose planing for these cohorts are underway. The company plans to report preliminary results from these dose escalating cohorts during 2020.